论文部分内容阅读
噻唑烷酮类药物吡格列酮（ｐｉｏｇｌｉｔａｚｏｎｅ，Ａｃｔｏｓ）已获美国ＦＤＡ许可用于治疗Ⅱ型糖尿病。本品可作为单一疗法用于２型糖尿病患者的治疗，亦可与二甲双胍，磺酰脲或胰岛素联用。ＦＤＡ建议接受本品者要进行常规肝功能测试。在美国，本品将由 Ｔａｋｅｄａ和
The thiazolidinone pioglitazone (Actos) has been approved by the U.S. FDA for the treatment of type 2 diabetes. This product can be used as monotherapy for the treatment of type 2 diabetes patients, but also with metformin, sulfonylurea or insulin. FDA recommended to accept this product to conduct routine liver function tests. In the United States, this product will be Takeda and